Sublingual administration of furosemide: New application of an old drug

British Journal of Clinical Pharmacology

Volumn 64, Issue 6, 2007, Pages 804-809

  Haegeli, Laurent ^a   Brunner La Rocca, Hans Peter ^a   Wenk, Markus ^a   Pfisterer, Matthias ^a   Drewe, Jürgen ^a   Krähenbühl, Stephan ^a  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

Absorption; Furosemide; Pharmacodynamics; Pharmacokinetics; Sublingual administration

Indexed keywords

FUROSEMIDE;

ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CONFIDENCE INTERVAL; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFECT; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; PRIORITY JOURNAL; SODIUM EXCRETION; URINALYSIS; URINE VOLUME;

ADMINISTRATION, ORAL; ADMINISTRATION, SUBLINGUAL; ADULT; CHEMISTRY, PHARMACEUTICAL; CROSS-OVER STUDIES; FUROSEMIDE; HUMANS; INJECTIONS, INTRAVENOUS; MALE;

EID: 36849046822     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2007.03035.x     Document Type: Article

References (14)

1. Swedberg K, Cleland J, Dargie H, Drexler H, Follath F, Komajda M, Tavazzi L, Smiseth OA, Gavazzi A, Haverich A, Hoes A, Jaarsma T, Korewicki J, Levy S, Linde C, Lopez-Sendon JL, Nieminen MS, Pierard L, Remme WJ. Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005). The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. Eur Heart J 2005 26 : 1115 40.
2. Brater DC. Resistance to loop diuretics. Why it happens and what to do about it. Drugs 1985 30 : 427 43.
3. Brater DC, Day B, Burdette A, Anderson S. Bumetanide and furosemide in heart failure. Kidney Int 1984 26 : 183 9.
4. Brater DC, Seiwell R, Anderson S, Burdette A, Dehmer GJ, Chennavasin P. Absorption and disposition of furosemide in congestive heart failure. Kidney Int 1982 22 : 171 6.
5. Vargo DL, Kramer WG, Black PK, Smith WB, Serpas T, Brater DC. Bioavailability, pharmacokinetics, and pharmacodynamics of torsemide and furosemide in patients with congestive heart failure. Clin Pharmacol Ther 1995 57 : 601 9.
6. Vasko MR, Cartwright DB, Knochel JP, Nixon JV, Brater DC. Furosemide absorption altered in decompensated congestive heart failure. Ann Intern Med 1985 102 : 314 8.
7. Lee MG, Chiou WL. Evaluation of potential causes for the incomplete bioavailability of furosemide: gastric first-pass metabolism. J Pharmacokinet Biopharm 1983 11 : 623 40.
8. Hammarlund-Udenaes M, Benet LZ. Furosemide pharmacokinetics and pharmacodynamics in health and disease - an update. J Pharmacokinet Biopharm 1989 17 : 1 46.
9. Grahnen A, Hammarlund M, Lundqvist T. Implications of intraindividual variability in bioavailability studies of furosemide. Eur J Clin Pharmacol 1984 27 : 595 602.
10. Hammarlund MM, Paalzow LK, Odlind B. Pharmacokinetics of furosemide in man after intravenous and oral administration. Application of moment analysis. Eur J Clin Pharmacol 1984 26 : 197 207.
11. McCrindle JL, Li Kam Wa TC, Barron W, Prescott LF. Effect of food on the absorption of furosemide and bumetanide in man. Br J Clin Pharmacol 1996 42 : 743 6.
12. Murray MD, Haag KM, Black PK, Hall SD, Brater DC. Variable furosemide absorption and poor predictability of response in elderly patients. Pharmacotherapy 1997 17 : 98 106.
13. Wenk M, Haegeli L, Brunner H, Krahenbuhl S. Determination of furosemide in plasma and urine using monolithic silica rod liquid chromatography. J Pharm Biomed Anal 2006 41 : 1367 70.
14. Zhang H, Zhang J, Streisand JB. Oral mucosal drug delivery: clinical pharmacokinetics and therapeutic applications. Clin Pharmacokinet 2002 41 : 661 80.